Navigation Links
New Recombinant XYNTHA Now Available for Patients with Hemophilia A
Date:9/8/2008

COLLEGEVILLE, Pa., Sept. 8 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that product shipments have begun for XYNTHA(TM) Antihemophilic Factor (Recombinant), Plasma/Albumin-Free, a new recombinant factor VIII product for both the control and prevention of bleeding episodes and surgical prophylaxis in patients with hemophilia A, a rare, inherited blood-clotting disorder.

XYNTHA is produced using state-of-the-art manufacturing and purification processes designed to reduce the risk of viral contamination. The manufacturing process for XYNTHA is completely albumin-free from start to finish, while the purification process utilizes a unique synthetic ligand totally free of animal materials and a nanofiltration step using a 35 nanometer pore-size filter.

"We believe the state-of-the-art manufacturing and purification processes used for XYNTHA make it an exciting new therapeutic option for many patients with hemophilia A," says Robert Repella, Executive Vice-President and General Manager, Wyeth BioPharma. "The introduction of XYNTHA is the culmination of many years of research and development, and demonstrates Wyeth's continued commitment to the hemophilia community." As an added convenience for patients, Wyeth's one-of-a-kind Rapid Reconstitution (R2) Kit is provided with XYNTHA. The R2 Kit is designed to help patients save time by allowing for ease of transportation and fewer steps during rapid reconstitution.

Shipments of the Company's current recombinant factor VIII product, ReFacto(R) Antihemophilic Factor (Recombinant) in the United States will be discontinued as of May 31, 2009. Wyeth anticipates that many patients using ReFacto may want to talk to their health care provider ab
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Deloitte Agrees to Acquire Recombinant Capital, A Leading Life Sciences Subscription Database and Advisory Services Firm
2. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
3. Sigma-Aldrich and MorphoSys Enter Into a Collaboration and Licensing Agreement for Recombinant Research Antibodies
4. STALLERGENES and Protein eXpert Enter Into a Partnership for Producing Mites Recombinant Allergens
5. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
6. Recombinant Human Renin - Crystallographic Grade
7. Free White Paper Now Available: How to get the most from your visit to electronica 2008 in Munich
8. Revolutionary New In-Office EVOLVE(R) Laser Prostate Treatment Available Throughout Western Oregon
9. Mymetics Corporation Information to be Available Through Standard & Poors Market Access Program
10. Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11
11. Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... MESA, Calif. , July 24, 2014  Now ... close to home. Rehealth Regenerative Therapies , located ... athletes and other physically active people a new health ... Regardless of age, countless patients suffer from ... sport activities, such as muscle tears, torn rotator cuff, ...
(Date:7/24/2014)... by group leader Yung-Eun Sung has announced that ... and nitrogen-doped graphenes which can be applied as ... cells. Yung-Eun Sung is both a group leader ... for Basic Science* (IBS) and a professor at ... great significance with regards to the development of ...
(Date:7/24/2014)... 24, 2014 Research and Markets ... Culture Market 2014-2018" report to their offering.  ... culture is the in vitro growth of plant or ... studies, and biopharmaceutical production. Cell culture is a crucial ... instruments and cell culture consumables are necessary for the ...
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. (NYSE ... and commercializing therapeutic products for the prevention and ... receipt of notice on July 18, 2014 from ... has accepted the CorMedix plan to regain compliance ... a result, the NYSE-MKT is continuing the Company,s ...
Breaking Biology Technology:Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3
... , SOUTHAMPTON, Pa., Jan. 11 Argyce LLC, the trustee ... will divest the remaining drug development program assets of Genaera ... bids to be received no later than February 12, 2010 ... combination. Any person interested in purchasing the assets or learning ...
... PAREXEL International Corporation (Nasdaq: PRXL ) today raised its ... 2010 ended December 31, 2009, and for the full Fiscal ... financial guidance takes into account the projected impact from second ... amount and timing of a previously announced restructuring charge, and ...
... 7 ... , ... -- Genedata, a leading provider of advanced software solutions for drug discovery and life science ... experienced unprecedented industry adoption with 7 out of the 25 leading pharmaceutical companies using Screener ...
Cached Biology Technology:Genaera Liquidating Trust To Sell Remaining Proprietary Assets 2PAREXEL Issues Updated Financial And Operational Information 2PAREXEL Issues Updated Financial And Operational Information 3PAREXEL Issues Updated Financial And Operational Information 4PAREXEL Issues Updated Financial And Operational Information 5Genedata at HCA Announces Banner Year for Genedata Screener at Leading Pharmaceutical Companies 2Genedata at HCA Announces Banner Year for Genedata Screener at Leading Pharmaceutical Companies 3
(Date:7/24/2014)... where electric cars ply silent freeways, solar panels blanket ... the earth, from howling winds and from the blazing ... it is technically and economically feasible to convert California,s ... energy. Published in Energy , the plan shows ... supply in California that could create tens of thousands ...
(Date:7/24/2014)... of researchers has developed a new nanoscale agent for ... for assessing the function and properties of the GI ... and treatment of gut diseases. , Illnesses ... and inflammatory bowel disease all occur in the intestine ... with diseases such as diabetes and Parkinson,s. , ...
(Date:7/24/2014)... this week for an all-day public forum on a ... (EPA) to dredge toxic sediment from an eight-mile stretch ... called the plan, which proposes removing 4.3 million cubic ... riverbed, one of the largest cleanups in the agency,s ... off-site. , "We need to ensure the future well-being ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4New imaging agent provides better picture of the gut 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2
... genomic DNA around nucleosomes in the cell nucleus makes ... (LMU) in Munich now describes a mechanism that allows ... transcription. In higher organisms the genomic DNA is ... called nucleosomes, each consisting of two pairs of four ...
... new report from the Institute of Medicine says schools should ... minutes of vigorous or moderate intensity activity during each school ... current evidence-based guidelines of at least an hour of vigorous ... which was released today. "Because children are in ...
... world,s largest and fastest growing open-access publishers, announces the ... and Biotechnology . A broad scope journal ... will provide a single open-access platform for diverse ... and discussed. Frontiers in Bioengineering and ...
Cached Biology News:Biochemistry: Unspooling DNA from nucleosomal disks 2Schools should provide students with daily physical activity, IOM recommends 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2
Agarase cleaves agarose to neoagaro-oligosaccharides, and is used for,quantitative, gentle recovery of DNA from low melting point agarose....
Request Info...
Recombinant Mouse Serpin A1/alpha-1-Antitrypsin, CF Protein Family: Coagulation, Serine Protease Regulators...
X-prolyl aminopeptidase (aminopeptidase P) 1, soluble...
Biology Products: